Remove Licensing Remove Pharmacy Remove Webinar
article thumbnail

NOW AVAILABLE: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers’ (press release) Review pricing/license options and download the full 2024 report We’re offering special discounted pricing if you order before April 8, 2024.

article thumbnail

Available for Preorder: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers. Review pricing/license options and place a preorder. Email Paula Fein ( paula@drugchannels.net ) if you’d like to bundle the report purchase with access to DCI’s video webinars. On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Pharmacist in the Value-Based Care Era

Fierce BioTech

Is your pharmacy ready to make the leap? Is your pharmacy ready to make the leap? Listing Image Inovalon Logo.png Listing Introduction Pharmacists are being called to operate at the top of their license to close gaps in care. Learn how your pharmacy can prepare today for a future of pharmacy focused on patient outcomes.

article thumbnail

How Pharma-Funded Groups Lie About Personal Drug Imports

Policy Prescription

NeedyMeds , a non-profit organization known for providing patients with help in finding pharmaceutical company-sponsored prescription assistance programs and other drug savings options, hosted a webinar about drug importation last year called “ Drug Importation: The topic everyone’s talking about.” The featured speaker was, Shabbir J.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

What of the increased possibilities for ‘replacement pharmacy compounding’ for weekly hospital supplies, and for routine manufacturing of cell and gene therapies without a marketing authorisation? In the same webinar, Emer Cooke, EMA Executive Director, countered, in relation to regional drug approvals, “Faster isn’t necessarily better.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023

Agency IQ

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40